Business Wire

BRENTWOOD, Tenn.--(BUSINESS WIRE)-- EOS Linx, an owner and operator of a growing, national electric vehicle (EV) charging network, has partnered with Clayton County Public Schools (CCPS) in Jonesboro, Georgia to install EV charging stations at schools across the district.

The installations, completed during the 2023-2024 school year, showcase the EOS Linx Aurora™ Charge Stations. The Aurora™ incorporates multiple EV chargers on each station, as well as a 75”... (continue reading...)

MONTREAL--(BUSINESS WIRE)--

Lomiko Metals awarded US$8.35m grant from the United States of America Department of Defense (“DoD”) in a Technology Investment Agreement (“TIA”) and funding of CA$4.9m from Natural Resources Canada to support further studies at La Loutre natural flake graphite project in Quebec, Canada

Lomiko Metals Inc. (TSX.V: LMR) (“Lomiko Metals” or the “Company”) is pleased to announce that it has been awarded a Department of... (continue reading...)

FORT LAUDERDALE, Fla.--(BUSINESS WIRE)-- Northrop Grumman Corporation (NYSE: NOC) announced today an agreement for access and use of NVIDIA AI software to accelerate development of some of the most advanced systems.

This industry-leading agreement, facilitated by Future Tech Enterprise, gives Northrop Grumman access to NVIDIA’s extensive portfolio of AI and generative AI software, its platforms and frameworks, including NVIDIA Omniverse.

The agreement also... (continue reading...)

SINGAPORE--(BUSINESS WIRE)-- AM Best has affirmed the Financial Strength Rating of A- (Excellent) and the Long-Term Issuer Credit Rating of “a-” (Excellent) of PT Asuransi Tokio Marine Indonesia (TMI) (Indonesia). The outlook of these Credit Ratings (ratings) is stable.

The ratings reflect TMI’s balance sheet strength, which AM Best assesses as strong, as well as its strong operating performance, limited business profile and appropriate enterprise risk... (continue reading...)

• Bayer will showcase latest data for growth driver NUBEQA® (darolutamide) and targeted radionuclide therapy XOFIGO® (radium Ra 223 dichloride)
• Bayer will also present a late-breaking abstract on the Phase I/II study of BAY 2927088 in patients with HER2-mutant non-small cell lung cancer (NSCLC), and data from VITRAKVI® in patients with tropomyosin receptor kinase (TRK) fusion lung cancer

Abstracts: 5022, 5083, TPS5122, TPS5127, e17040, LBA8598, 8570, 6095,... (continue reading...)